Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells $350,904.37 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) SVP Gunther Birznieks sold 42,431 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $350,904.37. Following the completion of the transaction, the senior vice president directly owned 494,197 shares of the company’s stock, valued at $4,087,009.19. This trade represents a 7.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Vanda Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:VNDA opened at $7.89 on Friday. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $7.60 and a 200-day simple moving average of $6.01. The company has a market capitalization of $466.38 million, a PE ratio of -2.12 and a beta of 0.55. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The company had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 611.3% in the second quarter. Stonepine Capital Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,180,000 after buying an additional 214,852 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Vanda Pharmaceuticals by 96.5% during the 2nd quarter. Squarepoint Ops LLC now owns 153,345 shares of the biopharmaceutical company’s stock worth $724,000 after purchasing an additional 75,295 shares in the last quarter. Kennedy Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 7.7% during the 2nd quarter. Kennedy Capital Management LLC now owns 237,468 shares of the biopharmaceutical company’s stock worth $1,121,000 after purchasing an additional 17,020 shares during the period. Geode Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 4.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock valued at $7,986,000 after purchasing an additional 77,997 shares in the last quarter. Finally, Readystate Asset Management LP acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at about $138,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Wall Street Analysts Forecast Growth

VNDA has been the subject of a number of research reports. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. HC Wainwright increased their price target on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Zacks Research downgraded shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th. Finally, Truist Financial initiated coverage on Vanda Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $18.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $14.90.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.